10x Genomics

TXG

Market cap $1.48B

PLEASANTON, Calif. , Oct. 9, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the third quarter ended September 30, 2025 after market close on Thursday, November 6, 2025.

SEATTLE--(BUSINESS WIRE)--Parse Biosciences Invalidates Scale Biosciences (now 10x Genomics) Patent.

10x Genomics, Inc. (NASDAQ:TXG ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Serge Saxonov - Co-Founder, CEO & Director Conference Call Participants Yih-Ming Tu - Morgan Stanley, Research Division Presentation Yih-Ming Tu Research Associate Good morning, everyone. Welcome to day 3 of the Morgan Stanley Global Healthcare Conference.

Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path for Blood Disorder Diagnosis, complementing bone marrow procedures PLEASANTON, Calif. and REHOVOT, Israel , Sept.

PLEASANTON, Calif. , Aug. 27, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, at 11:30 a.m.

Cathie Wood is most known for her bold, tech-first investing.

First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology PLEASANTON, Calif. , Aug. 19, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Xenium Protein, a powerful new addition to its Xenium Spatial platform that enables simultaneous RNA and protein detection in the same cell, on the same tissue section, all in a single automated run.

Tsakos Energy Navigation, 10x Genomics, Pan American Silver, Wolverine World Wide, and Interface top an efficiency-driven stock screen.

10x Genomics, Inc. (NASDAQ:TXG ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Adam S. Taich - CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer Cassie Corneau - Manager of Investor Relations & Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Conference Call Participants Daniel Anthony Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Jacob Krahenbuhl - William Blair & Company L.L.C.

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.